Literature DB >> 3611500

A phospholipase inhibitor modifies the pulmonary damage associated with peritonitis in rabbits.

D Tighe, R Moss, J Parker-Williams, J Hynd, E D Bennett.   

Abstract

Peritonitis has been produced in rabbits by the spreading of 5 ml of caecal contents throughout the peritoneal cavity. After sacrifice at 5 h, electron microscopy revealed a increase of 600% in PMN and 1200% in lymphocytes in the pulmonary capillaries of the test animals when compared to the sham operated group. The pulmonary capillaries in the test group showed a 27% reduction in their luminal area, which was associated with a 73% reduction in their patency due to occlusion by WBC and cell debris. In addition there was endothelial and epithelial disruption with basement membrane exposure. The PMN were degranulated and adherent to the pulmonary endothelium. Pretreatment with the phospholipase inhibitor, mepacrine, significantly attenuated these responses, so that there was only an increase of 200% in PMN and 450% in lymphocytes in the lungs with no evidence of degranulation or adhesion to the pulmonary endothelium. Furthermore there was no change in capillary luminal area when compared to the sham operated group. In addition there was only slight damage to the endothelium and epithelium with no exposure of the basement membrane. Peripheral WBC in both the test and mepacrine groups showed a similar 62% and 75% reduction after 5 h when compared to baseline values. The sham group did not show this change. These results suggest that phospholipase inhibition plays an important role in attenuating the pulmonary response to faecal peritonitis and may be of potential benefit in treating clinical septicaemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3611500     DOI: 10.1007/bf00265119

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  15 in total

1.  A MORPHOMETRIC STUDY ON THE THICKNESS OF THE PULMONARY AIR-BLOOD BARRIER.

Authors:  E R WEIBEL; B W KNIGHT
Journal:  J Cell Biol       Date:  1964-06       Impact factor: 10.539

2.  Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A.

Authors:  A Pappu; K Y Hostetler
Journal:  Biochem Pharmacol       Date:  1984-05-15       Impact factor: 5.858

3.  Acute respiratory distress in adults.

Authors:  D G Ashbaugh; D B Bigelow; T L Petty; B E Levine
Journal:  Lancet       Date:  1967-08-12       Impact factor: 79.321

4.  Pulmonary hypertension correlated to pulmonary thromboxane synthesis.

Authors:  J C Frölich; M Ogletree; B A Peskar; K L Brigham
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1980

5.  The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs.

Authors:  G J Blackwell; W G Duncombe; R J Flower; M F Parsons; J R Vane
Journal:  Br J Pharmacol       Date:  1977-02       Impact factor: 8.739

6.  Altered metabolism of phospholipids in the lung of rats with peritonitis.

Authors:  P von Wichert; U Wiegers; W Stephan; A Huck; P Eckert; K Riesner
Journal:  Res Exp Med (Berl)       Date:  1978-06-12

7.  Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock.

Authors:  P Vadas; J B Hay
Journal:  Can J Physiol Pharmacol       Date:  1983-06       Impact factor: 2.273

8.  Influence of septic shock upon phosphatidylcholine remodeling mechanism in rat lung.

Authors:  P von Wichert; M Temmesfeld; W Meyer
Journal:  Biochim Biophys Acta       Date:  1981-06-23

9.  Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock.

Authors:  P Vadas
Journal:  J Lab Clin Med       Date:  1984-12

10.  Acute effects of Escherichia coli endotoxin on the pulmonary microcirculation of anesthetized sheep structure:function relationships.

Authors:  B Meyrick; K L Brigham
Journal:  Lab Invest       Date:  1983-04       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.